Ratings by William Blair (Matt Phipps)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
6/8/2021 Biogen BIIB Upgrade Outperform
(Market Perform)
395.85
(300.19)
-24.17% Details
4/8/2021 F-Star Therapeutics Inc. FSTX New Coverage Outperform
(N/A)
10.20
(7.59)
-25.59% Details
4/8/2021 Merus N.V. MRUS New Coverage Outperform
(N/A)
22.28
(25.63)
15.04% Details
11/9/2020 Codiak Biosciences Inc. CDAK New Coverage Outperform
(N/A)
9.09
(19.11)
110.23% Details
7/21/2020 Dynavax Technologies DVAX Maintain Outperform
(N/A)
 
 
  Details
5/5/2020 Portola Pharmaceuticals PTLA Downgrade Market Perform
(Outperform)
7.76
(18.03)
132.35% Details
12/18/2019 Aduro Biotech ADRO Downgrade Market Perform
(Outperform)
1.15
(14.60)
1169.57% Details
9/16/2019 Atara Biotherapeutics ATRA Maintain Outperform
(N/A)
 
 
  Details
9/11/2019 PhaseBio Pharmaceuticals Inc. PHAS New Coverage Outperform
(N/A)
5.20
(2.89)
-44.42% Details
7/16/2019 Atara Biotherapeutics ATRA Maintain Outperform
(N/A)
 
 
  Details
3/21/2019 Biogen BIIB Downgrade Market Perform
(Outperform)
320.59
(395.85)
23.48% Details